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The gene APM1, also known as GBP28 or AdipoQ,
encodes adiponectin, a protein that is exclusively
expressed in adipose tissue [1]. APM1 is located on
chromosome 3q27 [2], where recent studies using
genome-scans have located a susceptibility locus for
type 2 diabetes and for several traits of the metabolic
syndrome [3,4]. Furthermore, recent mutation screen-
ings have detected 13 single nucleotide polymor-
phisms (SNPs) of the APM1 gene in Japanese and
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This cross-sectional study analyzed the effects of two single nucleotide polymorphisms (SNP) of
the adiponectin gene, SNP45 and SNP276, on hyperglycemia in indigenous Taiwanese, and
whether central obesity modulates the effects of these SNPs. Overall, 550 indigenous Taiwanese
were recruited for this cross-sectional study. The subjects were categorized into a hyperglycemic
group if fasting plasma glucose was > 126 mg/dL (n = 88) or the control group if fasting plasma
glucose was < 100 mg/dL (n = 462). The SNP276 TT homozygote carried greater hyperglycemia
risk than SNP276 GG [odds ratio (OR) = 2.67, 95% confidence interval (CI) = 1.05–6.78], but not
heterozygote (OR = 1.54, 95% CI = 0.95–2.50). SNP45 T > G was not associated with hyperglycemia
risk. In multivariate-adjusted modeling, we found a significant relationship between SNP276 T
carriers (GT + TT) (OR = 2.06, 95% CI = 1.10–3.88) and central obesity (OR = 4.50, 95% CI = 1.91–
10.61) with hyperglycemia. Compared with non-central-obese carriers of SNP276 GG, non-
central-obese SNP276 T carriers, and central obese subjects with SNP276 GG and SNP276 T carriers
had 5.50, 8.31 and 13.76-fold, respectively, higher risks for hyperglycemia; obese carriers of the 
T-containing variants experienced a combined risk for hyperglycemia. Furthermore, the hyper-
glycemic risks were more pronounced in leaner (non-central-obese) individuals carrying the T
variant than the central-obese individuals. The adiponectin SNP276 T variant and central obesity
had independent and additive effects on hyperglycemia risks. These findings may provide valu-
able information regarding preventive strategies that might be useful to prevent or treat diabetes
and its related complications.
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French populations [5,6]. Among these 13 SNPs, two [a
silent T to G substitution in exon 2 (+ 45 T > G) and a G
to T substitution in intron 2 (+276 G>T)] are commonly
associated with type 2 diabetes or insulin resistance in
Asians [5] and in Caucasians in France and Italy [6,7].
Weyer et al found a stronger association between
decreases in adiponectin levels and obesity in people
with type 2 diabetes than in healthy subjects [8]. In a
genetic mouse model of obesity and lipoatrophy to
explore the possible mechanisms underlying the asso-
ciation between decreased levels of adiponectin and
insulin resistance, the administration of recombinant
adiponectin in diabetic mice ameliorated insulin sen-
sitivity by reducing triglyceride levels in muscle and
liver through an increase in fatty acid β-oxidation
[9,10]. The findings of these studies strongly suggest
that adiponectin plays a role in the pathogenesis of
insulin resistance and type 2 diabetes. In addition,
there is a greater likelihood that insulin resistance and
endothelial dysfunction will progress to type 2 dia-
betes and atherosclerosis in people with central obesity
[11]. While a relationship between adiponectin and
obesity seems clear, the overall effects of this relation-
ship are unknown.
The risk of developing hyperglycemia or diabetes
parallels the steadily increasing rates of obesity [12].
People of Polynesian origin are considered to express
a “thrifty” genotype, a term originally hypothesized by
Neel [13]. The thrifty genotype is an evolutionary de-
velopment in energy storage metabolism, causing
conservation of energy during food deprivation and
efficient fat accumulation in response to abundant
food supply. This phenomenon partially explains the
higher prevalence of obesity in many Polynesian com-
munities, including native Hawaiians [14], indigenous
Maori and other Pacific Islanders in New Zealand [15]
and other Pacific Islanders [16], relative to other ethnic-
ities. Although, to Westerners, indigenous Taiwanese
may look similar to other Asians, they are genetically
different from Han Chinese, and recent mitochondria
DNA analysis links indigenous Taiwanese with
Polynesians [17]. According to the 1993–1996 National
Nutrition Survey in Taiwan administered by the
Department of Health, adult indigenous men and
women (36.3% and 31.0%, respectively) have a higher
prevalence of abdominal obesity based on the waist-
to-hip ratio than the rest of the population, who are
mostly of Han Chinese origin (14.1–25.5% and
8.1–21.5%, respectively) [18].
We have previously investigated the associations
between some genetic variations and the extent of obe-
sity in this indigenous community [19,20]. To the best
of our knowledge, no study has compared the relative
contribution of SNP45 and SNP276 in the context of
central obesity on glycemic status in Taiwan or in other
Polynesian indigenous groups. Therefore, this study
investigated the relative influence of two genetic vari-
ants at the adiponectin locus (+45 T>G and+276 G>T)
on glycemic status in indigenous Taiwanese and the
possible role of central obesity on the impact of these
SNPs on hyperglycemia in this population.
METHODS
Study population
This study was a population-based epidemiological
survey in an indigenous community living in Majia
Township, Pingtung County, in Southern Taiwan. Majia
Township consists of six villages. The area and popu-
lation of this township is approximately 78 m2 and
6,400 people, respectively. Ninety-five percent of the
people living in this township are aborigines [21]. We
performed community health examinations between
August 2003 and February 2004. A total of 749 subjects
were recruited in this study.
To reduce genetic variability, we included subjects
whose parents were from the same tribe (2 tribes).
After excluding non-indigenous and indigenous
Taiwanese with more than one lineage, we were left
with a total of 616 unrelated subjects for this cross-
sectional study. Based on the classification of the
American Diabetes Association [22], we categorized
subjects with fasting plasma glucose (FPG) > 126 mg/
dL or currently taking antidiabetic medications into a
hyperglycemic group (n = 88) and those with FPG
< 100 mg/dL into a control group (n = 462). Insulin
resistance was assessed by the homeostasis model
assessment of insulin resistance [HOMA-IR = insulin
(μU/ml) × FPG (mmol/L)/22.5] [23]. The protocol for
this study was approved by the Human Ethics Com-
mittee of Kaohsiung Medical University.
Anthropometric measurements and 
data collection
Anthropometric measurements (weight, height,
waist and hip circumference) were done by trained
interviewers. Central obesity was defined as waist
circumference > 90 cm in men or > 80 cm in women,
based on standards established by the International
Diabetes Federation [24]. Trained interviewers assisted
the participants as they completed a questionnaire
collecting demographic information (age, education
and tribal background) and lifestyle factors (drink-
ing, betel quid chewing, smoking, and consumption
of food groups related to glycemic control).
Metabolic parameters and genotype
measurements
Venous blood samples were drawn and stored at 4°C.
The whole-blood samples were then sent to the labora-
tory of the Graduate Institute of Medicine at Kaohsiung
Medical University. Aliquots of fresh serum were
sent for routine clinical blood measurements (triglyc-
eride, cholesterol, creatinine, uric acid and blood
urea nitrogen) by an auto-analyzer (Beckman LX-20,
Palo Alto, CA, USA) at the Department of Laboratory
Medicine in Kaohsiung Medical University Hospital.
FPG was measured using the Freestyle Blood Glucose
Monitoring System (Abbott Diabetes Care, Alameda,
CA, USA). Plasma adiponectin was measured by radio-
immunoassay (Linco Research, St. Charles, MO, USA).
DNA was extracted using a commercial kit (Puregene,
Gentra Systems Inc., Minneapolis, MN, USA) and
stored at –20°C until DNA genotyping. SNP276
(rs1501299) and SNP45 (rs2241766) were chosen for
genotyping based on literature reviews and on the
higher allele frequencies in the SNP database [25].
SNP276 was detected by real-time polymerase
chain reaction (ABI 7900; Applied Biosystems, Foster
City, CA, USA). This assay is based on hybridization
probes labeled with florescent dyes that allow fluo-
rescence resonance energy transfer as two probes hy-
bridize to adjacent sequences on the same unlabeled
complementary strand. When a probe hybridizes over
a sequence variant and forms a mismatch, the des-
tabilized duplex causes a change in melting tempe-
rature from the completely complimentary duplex.
SNP genotyping was then performed using a melting
curve. The forward and reverse primers used for DNA
amplification were 5’-TTC ATC ACA GAC CTC CTA
CAC TGA-3’ and 5’-TCC TGT GTC TAG GCT TAG
TTA AT-3’. The hybridization probes were 5’-FAM-
AAA CTA TAT GAA GTC ATT CAT-3’ and 5’-VIC-
ACT ATA ATG AAG GCA TTC AT-3’. The conditions
of the TaqMan reaction were as follows: 50°C for 
2 minutes, 95°C for 10 minutes and 40 cycles of 95°C
for 15 seconds and 60°C for 1 minute. We also ran-
domly selected about 60 subjects (∼10%) and repeated
the genotyping for adiponectin SNP276 using the
same method. Except for one ambiguous genotype
from one subject, the results of genotyping for the
repeated samples were comparable with those of the
first run.
SNP45 was genotyped using polymerase chain
reaction and restriction length polymorphism. The
primers were 5’-TAT CAG TGT AGG AGG TCT GTG
ATG-3’ and 5’-CAT CAC AGA CCT CCT ACA CTG
ATA-3’. Amplification of the SNP45 for adiponectin
was done for 35 cycles of denaturation at 95°C for 30
seconds, annealing at 65°C for 2 minutes and extension
at 72°C for 2 minutes. The amplified products were
digested using Sma I, and the resulting fragments
were separated by 2% agarose gel electrophoresis.
Upon digestion with Sma I, the presence of the restric-
tion site resulted in fragments of 220 bp and 152 bp in
size, and 372 bp for the uncut allele.
Statistical analysis
All statistical operations were performed using SPSS
version 11.5 (SPSS Inc., Chicago, IL, USA). We used 
student t tests or analysis of variance to analyze dif-
ferences in continuous variables. For variables with-
out normal distributions, data were log-transformed
before testing. The distribution of categorical vari-
ables and genotypes were analyzed by χ2 tests or
with Fischer’s exact test for variables with n < 5. A
goodness-of-fit χ2 test was used to test the Hardy-
Weinberg equilibrium comparing the observed num-
ber of subjects for each genotype with the number
expected. Linear regression was used to test the lin-
ear trend of metabolic traits across different glycemic
states or genotypes. A multiple logistic regression
model was used to obtain adjusted odds ratios (OR)
and the 95% confidence intervals (CI). Differences were
considered significant when p < 0.05 or when the 95%
CI did not include 1.
RESULTS
Demographic and metabolic characteristics
of subjects
Clinical characteristics of control and hyperglycemia
groups are presented in Table 1. There were no sig-
nificant differences between the two groups in terms
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of sex (males, 36.1% vs. 39.8%), tribal distribution
(Paiwan, 89.3% vs. 87.5%) or education level (below
junior high school, 89.0% vs. 94.3%). The hypergly-
cemic group of indigenous Taiwanese had significantly
higher weight, FPG, insulin, HOMA-IR and plasma
triglyceride levels than the control subjects (p < 0.05).
There were no significant differences between the two
groups in terms of tobacco, alcohol or betel quid use
or the consumption of carbohydrate-containing food
groups such as cereals, fruits, vegetables and sweet-
ened drinks (data not shown).
Associations between adiponectin SNPs
and FPG
We compared the presence of SNP276 and SNP45 in
the adiponectin gene with glycemic status (Table 2),
and found that those with the SNP276 TT homozygote
were at significantly greater risk of hyperglycemia than
those with the wild type SNP276 GG (OR = 2.67, 95%
CI = 1.05–6.78; p = 0.039). Similarly, those carrying
SNP276 T variant also had greater risk of hyper-
glycemia than those carrying the G variant (OR=1.59,
95% CI=1.10–2.29; p=0.014). There was no association
between SNP45 T > G and hyperglycemia. We found
that the SNP276 G > T and SNP45 T > G polymor-
phisms were in Hardy-Weinberg equilibrium (Table 2).
We further compared the clinical characteristics 
of the subjects carrying the adiponectin SNP276 ge-
notype (Table 3). For the SNP276 genotypes, body
weight (p for trend = 0.039), adiponectin (p for trend =
0.017) and FPG (p for trend = 0.001) were positively
correlated with the SNP276 T variant, and HOMA-IR
was marginally correlated (p for trend = 0.056). Adi-
ponectin (p for trend = 0.017) was inversely correlated
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Table 2. Genotype and allele distribution for SNP276 G > T and SNP45 T > G in the adiponectin gene in hyperglycemic
and control subjects (n = 550)*
Control group Hyperglycemia group Unadjusted OR
p HWE†
(n = 462) (n = 88) (95% CI)
SNP276
GG 298 (64.5) 46 (52.3) 1 0.830/0.924
GT 147 (31.9) 35 (39.8) 1.54 (0.95–2.50) 0.078
TT 17 (3.7) 7 (7.9) 2.67 (1.05–6.78) 0.039
G allele 743 (80.4) 127 (72.7) 1
T allele 181 (19.6) 49 (27.8) 1.59 (1.10–2.29) 0.014
SNP45
TT 193 (41.8) 43 (48.9) 1 0.814/0.304
TG 213 (46.1) 34 (38.6) 0.72 (0.44–1.17) 0.182
GG 56 (12.1) 11 (12.5) 0.88 (0.43–1.82) 0.734
T allele 599 (64.8) 120 (68.2) 1
G allele 325 (35.2) 56 (31.8) 0.86 (0.61–1.21) 0.860
*Data are expressed as n (%) or odds ratio (95% confidence interval); †control group/hyperglycemia group. OR = Odds ratio; CI = con-
fidence interval; HWE = Hardy-Weinberg equilibrium; SNP = single nucleotide polymorphism.
Table 1. Clinical characteristics of hyperglycemic and control subjects*
Control group (n = 462) Hyperglycemia group (n = 88) p†
Age (yr) 61.9 ± 13.2 64.0 ± 10.6 0.146
Weight (kg) 61.6 ± 13.2 65.1 ± 15.5 0.027
Body mass index (kg/m2) 27.3 ± 8.0 28.5 ± 5.2 0.157
Waist (cm) 84.9 ± 12.3 90.8 ± 11.1 < 0.001
Adiponectin (μg/mL) 9.7 ± 9.1 7.8 ± 6.0 0.088
Plasma glucose (mg/dL) 87.7 ± 8.3 147.0 ± 53.9 < 0.001
Insulin (μU/mL) 3.6 ± 5.5 6.3 ± 7.0 < 0.001
HOMA-IR 0.8 ± 1.1 2.2 ± 2.8 < 0.001
Cholesterol (mg/dL) 181.8 ± 36.6 184.0 ± 38.9 0.609
Triglyceride (mg/dL) 126.5 ± 114.2 158.3 ± 147.8 0.024
Uric acid (mg/dL) 6.9 ± 2.0 7.2 ± 2.1 0.201
*Data presented as mean ± standard deviation; †t test. HOMA-IR = Homeostasis model assessment of insulin resistance.
with the T variant. The three genotypes at SNP45
T > G had similar metabolic traits. On examination of
the association between the biochemical parameters
and the SNP276 G > T genotypes within the control or
hyperglycemia subjects, there were no significant cor-
relations between clinical parameters and the adipo-
nectin SNP276 GG, GT or TT genotypes in either the
control or hyperglycemic subjects.
Relationship between adiponectin SNP276
genotypes and/or central obesity and FPG
Multivariate logistic regression analysis was used to
analyze the relationship between SNP276 and/or
central obesity with hyperglycemia. After controlling
for age, sex, tribe, plasma adiponectin, serum triglyc-
eride, stroke, heart disease, gout, and HOMA-IR, we
found that the adiponectin SNP276 T-containing
genotypes (GT + TT) (OR = 2.06, 95% CI = 1.10–3.88)
and central obesity (OR = 4.50, 95% CI = 1.91–10.61)
were significantly associated with hyperglycemic
status in this indigenous population. We further
investigated the independent and joint effects of 
the SNP276 T containing genotypes and central obe-
sity on hyperglycemic status (Table 4). Compared
with non-central-obese carriers of SNP276 GG, non-
central-obese subjects with SNP276 (GT or TT), and
central-obese subjects with SNP276 GG or with
SNP276 (GT or TT) respectively, had a 5.50 (95%
CI = 1.17–25.85), 8.31 (95% CI = 2.23–31.14) and 13.76-
fold (95% CI = 3.53–53.63), respectively, greater risk of
hyperglycemia. Obese carriers of the T-containing
variant of SNP276 were found to be at additive risk for
hyperglycemia. Furthermore, the effect of the SNP276
T variants on hyperglycemic status was greater in
leaner (non-central-obese) subjects (5.5/1.0) than in
subjects with central obesity (13.76/8.31).
DISCUSSION
In this study, we compared the effect of two genetic
variants at the adiponectin locus (+ 276 G > T and + 45
T > G) on glycemic status in indigenous groups in
Southern Taiwan and further investigated whether
central obesity might modulate the impact of these
polymorphisms on hyperglycemia in this popu-
lation. We found evidence that both the SNP276
T variant of the adiponectin gene and central obesity
are independent risk factors for hyperglycemia
(OR = 2.06 and 4.50, respectively) in this population.
Leaner individuals carrying the T variant were also
more likely to be hyperglycemic. Finally, we found
that subjects carrying the SNP276 T-containing ge-
notypes (GT or TT) and who were also centrally
obese had the greatest risk of being hyperglycemic
(OR = 13.76), suggesting that obese carriers of T-
containing variants were at an additive risk of being
hyperglycemic.
Other studies have also found an association
between the mutant T allele and adverse glucose out-
comes, as well as lipid profiles [26–30]. Filippi et al
[26] found a correlation between this T allele and
Adiponectin SNP276 and hyperglycemia risk
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Table 3. Clinical characteristics of the subjects according to SNP276 G > T and SNP45 T > G variants of the adiponectin
gene (n = 550)*
SNP276 G > T
p†
GG GT TT
Age (yr) 62.4 ± 12.8 61.8 ± 13.0 63.0 ± 12.4 0.867
Weight (kg) 61.3 ± 13.9 63.4 ± 12.9 65.6 ± 14.5 0.039
Body mass index (kg/m2) 27.4 ± 9.0 27.5 ± 4.7 27.4 ± 4.6 0.919
Waist (cm) 85.3 ± 12.8 86.8 ± 11.4 86.9 ± 10.8 0.183
Adiponectin (μg/dL) 9.8 ± 8.5 8.8 ± 9.0 6.1 ± 4.5 0.017
Plasma glucose (mg/dL) 90.5 ± 28.4 94.8 ± 35.9 115.3 ± 53.1 0.001
Insulin (μU/mL) 4.1 ± 6.7 4.1 ± 4.0 3.5 ± 3.5 0.139
HOMA-IR 1.0 ± 1.9 1.0 ± 0.9 1.2 ± 1.7 0.056
Cholesterol (mg/dL) 182.3 ± 37.4 181.5 ± 35.7 184.2 ± 40.3 0.986
Triglyceride (mg/dL) 136.3 ± 134.8 119.4 ± 71.4 157.1 ± 185.7 0.917
Uric acid (mg/dL) 7.0 ± 2.0 7.1 ± 1.9 6.4 ± 2.1 0.417
*Data presented as mean ± standard deviation; †simple linear regression (p for trend) was used to determine the profiles of the clinical
characteristics among the different adiponectin SNP276 G > T genotypes. HOMA-IR = Homeostasis model assessment of insulin
resistance; SNP = single nucleotide polymorphism.
lower serum adiponectin concentrations and greater
insulin resistance in Italians. In cohort studies, indi-
viduals with the T allele were more susceptible to
further development to type 2 diabetes [27]. The T
allele has also been associated with elevated low-
density lipoprotein and reduced high-density lipopro-
tein [28] in Canadians and higher risk for cardiovascu
lar diseases in Americans [29]. The current study did
not find an association between SNP45 and glycemic
status, although some reports have associated SNP45
with altered glucose metabolism [5,7]. One recent
cohort study also found that glucose-intolerant sub-
jects carrying both SNP45 G and SNP276 T had a 4.5-
fold greater risk for developing type 2 diabetes than
glucose-intolerant subjects not carrying either of
these alleles [27]. Similar observations have been
made in case-control studies in Germany [30] and
Italy [7]. However, one study of Caucasians in France
did not find an association between the two SNPs
and the risk of type 2 diabetes [6]. The reason for the
differences in these findings is not yet known, but
might be attributable to genetic differences in the pop-
ulations they studied.
Our study found that the SNP276 mutant T allele,
but not the G allele, was associated with greater risk for
hyperglycemia. This study found a relationship be-
tween SNP276, a silent polymorphism of the adip-
onectin gene, and increased risk for hyperglycemia
(OR = 2.06, 95% CI = 1.10–3.88). However, it is not yet
clear how an intron polymorphism can alter the risk
for hyperglycemia. A polymorphism need not be
functionally relevant itself, though it can be in com-
plete or near-complete linkage disequilibrium with
other still undiscovered SNPs of the adiponectin gene
or other genes modulating the expression of adip-
onectin or its biological activities. We found a signifi-
cant dose-dependent relationship between the at-risk
T allele and decreases in concentrations of adip-
onectin (p for trend = 0.017) and increases in FPG (p
for trend=0.001), indicating that SNP276 in an intron of
the adiponectin gene may modulate glucose home-
ostasis by altering the expression of the adiponectin
protein. Previously, Menzaghi et al [7] reported the
SNP276 G > T to be in almost complete linkage dise-
quilibrium with an “A” insertion in the 3’untrans-
lated region of the adiponectin gene (SNP+ 2019). The
3’ untranslated regions are generally considered impor-
tant in the regulation of gene expression. It has been
proposed that the + 2019 insertion may alter one of the
regulatory elements of the adiponectin 3’ untrans-
lated region and subsequently affect mRNA translation
or degradation [31,32]. Earlier case-control and cross-
sectional studies have shown associations between
reduced adiponectin levels with diabetes, obesity
and cardiovascular disease [5–7]. Very recently, a large
prospective study suggested that higher adiponectin
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Table 4. Adjusted odds ratios for risks of hyperglycemia according to SNP276 G > T genotypes and central obesity by
multiple logistic regression analysis (n = 550)*
Variables
Hyperglycemia Control Adjusted OR (95% CI) 
group group Model 1 Model 2† Model 3‡
Adiponectin SNP276
GG 46 (52.3) 298 (64.5) 1 1 –
GT + TT 42 (47.7) 164 (35.5) 1.64 (1.03–1.60) 2.06 (1.10–3.88) –
Central obesity
No 20 (22.7) 196 (43.2) – 1 –
Yes 68 (77.3) 258 (56.8) – 4.50 (1.91–10.61) –
SNP276 and central obesity
GG + non-central obesity 9 (10.2) 135 (29.7) – – 1
(GT + TT) + non-central 11 (12.5) 61 (13.4) – – 5.50 (1.17–25.85)
obesity
GG + central obesity 37 (42.0) 156 (34.4) – – 8.31 (2.22–31.14)
(GT + TT) + central obesity 31 (35.3) 102 (22.5) – – 13.76 (3.53–53.63)
*Data presented as n (%) or adjusted odds ratio (95% confidence interval); †model 2 was adjusted for age, sex and tribal background;
‡model 3 was adjusted for age, sex, tribal background, adiponectin, hypertriglyceridemia, homeostasis model assessment of insulin
resistance, gout, stroke and heart disease. OR = Odds ratio; CI = confidence interval; SNP = single nucleotide polymorphism.
concentrations might predict lower risks for type 2
diabetes [33]. Such findings suggest that adiponectin
may not only serve as a marker but also as a risk factor
for diabetes.
Abdominal obesity is thought to play a role in the
parallel progression of insulin resistance to type 2
diabetes and in the progression from endothelial dys-
function to atherosclerosis [11]. In addition, there have
been reports of associations between APM1 gene poly-
morphisms and various types of obesity in different
populations [7,30]. The indigenous individuals with
central obesity in this study were 4.5 times more likely
to be hyperglycemic than those without central obe-
sity (OR = 4.50, 95% CI = 1.91–10.61). We also found
that leaner individuals carrying the T variant were
5.5 times more likely to be hyperglycemic than those
not carrying this variant, whereas obese individuals
carrying the T variant (OR = 13.76) were at only 1.65
times the risk (13.76/8.31). Filippi et al [26] also
reported that only leaner individuals (body mass index
< 26.2 kg/m2) carrying the SNP276 G > T variant had
significantly greater insulin resistance than those
with the SNP276 GG genotypes, while obese individ-
uals (body mass index ≥ 26.2 kg/m2) showed similar
resistance to insulin, regardless of whether they were
carrying the SNP276 G > T variant or the SNP276 GG
genotype. Based on this evidence, the impact of the
SNP276 gene variants on hyperglycemia and insulin
sensitivity seems to be more apparent in leaner indi-
viduals than in centrally obese individuals.
Studies from animal models and human subjects
have demonstrated that adiponectin, which is abun-
dantly expressed in adipocytes, is an insulin-sensitiz-
ing hormone that is negatively regulated by obesity
[34]. Most of the metabolic effects of adiponectin are
dependent on the activation of adenosine monophos-
phate-dependent kinase [35]. AMP-dependent kinase
is a fuel-sensing enzyme [36] that mediates increased
glucose uptake, reduced hepatic glucose production
and increased adenosine-5’-triphosphate production.
The mechanism through which plasma adiponectin
levels are reduced in individuals with visceral fat is
not yet fully understood, but increases in inflammatory
cytokine (e.g. tumor necrosis factor-α) secretion from
accumulated visceral fat seems to inhibit adiponectin
production [37]. This partially explains our findings
that adiponectin levels are generally decreased in obese
individuals and in people with inflammatory-related
diseases such as diabetes and cardiovascular diseases
[3,4,8,9] Hypoadiponectinemia can be caused either by
interactions between genetic variations in the adipo-
nectin gene or by the environmental factors that cause
obesity. Our findings, as well as reports by Filippi et al
[26], suggest that the effect of the gene variant on the
hyperglycemic state in obese individuals may be too
small to be detected. It is possible that the effects of
central obesity on adiponectin levels or the production
of inflammatory cytokines overwhelm the effect of
the adiponectin SNP276 genetic variants on glycemic
state, leading to more apparent effects of adiponectin
SNP276 polymorphisms on leaner individuals.
There are several limitations in the current study.
First, this study had a relatively small sample size,
and the study population only included two indi-
genous tribes. Therefore, the results of this study
may not be representative of an ordinal indigenous
tribe in Taiwan. Thus a larger sample size is needed
to confirm our present results. Second, the possibility
of linkage disequilibrium could not be determined
by assuming simple associations between one poly-
morphism. We have suggested possible roles of adi-
ponectin in the development of insulin resistance or
the atherogenic state based on the available evidence
[9,10]. The exact mechanisms underlying the role 
of adiponectin SNP276 in the development of dia-
betes or atherosclerosis warrants further functional
experimentation.
In conclusion, we found a higher prevalence of the
SNP276 T variant of the adiponectin gene in hyper-
glycemic indigenous Taiwanese. In our multivariate
logistic regression model, the SNP276 T-containing
genotypes and central obesity were independent risk
factors for hyperglycemia, and the presence of both
factors in combination increased the risk for hyper-
glycemia. The effects of the SNP276 T variant on
hyperglycemia are more pronounced in leaner indi-
viduals than in obese individuals, suggesting that obe-
sity may serve as a modifiable factor for adiponectin
SNP276 in modulating the risk for hyperglycemia.
Because of the worldwide epidemic of early age onset
of obesity, there will probably be an increase in the
contribution of adiponectin to diabetes and cardiovas-
cular risk. In light of this likely trend, a better under-
standing of the relationship between adiponectin gene
variants or adiponectin levels in combination of obe-
sity may help better assess the risks for diabetes or car-
diovascular disease in susceptible individuals; such
knowledge may allow for prevention at an earlier age.
Adiponectin SNP276 and hyperglycemia risk
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此橫斷面研究目的為探討台灣原住民脂締素（adiponectin）之基因多型性，
SNP45、SNP276與中央型肥胖與高血糖之相關性。本研究共招募 550 位台灣原住
民。高血糖之定義為禁食血糖 ≥ 126 mg/dL（n = 88）及對照組（正常血糖）則為禁
食血糖 < 100 mg/dL（n = 462）。SNP276 TT 同型結合子者相對於 SNP276 GG 同
型結合子者有 2.67 倍罹患高血糖之危險性（OR = 2.76，95% CI = 1.06–6.78），但
攜帶異型結合子者（GT）相對於 SNP276 GG 同型結合子則無顯著差異（OR = 
1.54，95% CI = 0.95–2.50）。而 SNP45 T＞ G 與高血糖則無顯著相關性。利用複
邏輯回歸分析發現，相較於 SNP276 GG，攜帶 SNP276 T 對偶基因者（GT＋ TT）
有 2.06 倍（OR = 2.06，95% CI = 1.10–3.88）高血糖之危險性；而相較於無中央
型肥胖體位者，中央型肥胖個案有 4.50 倍（OR = 4.50，95% CI = 1.91–10.61）高
血糖之危險性。更進一步，相較於無中央型肥胖體位者且 SNP276 攜帶 GG 基因型
者，無中央型肥胖且 SNP276 帶有 T 對偶基因者、有中央型肥胖且攜帶 SNP276 GG 
基因型者或攜帶 SNP276 含 T 對偶基因者罹患高血糖之危險性分別為 5.50 倍、8.31 
倍與 13.76 倍。結果顯示，中央型肥胖與 SNP 帶有 T 對偶基因者對於罹患高血糖之
危險性具有加成作用。結論，脂締素基因 SNP276 攜帶 T 對偶基因和中央型肥胖者與
高血糖危險性具有獨立以及加成之相關性。此研究結果提供原住民糖尿病以及心血管
疾病預防策略。
關鍵詞：脂締素、脂締素 SNP276基因多型性、中央型肥胖、高血糖、台灣原住民
（高雄醫誌 2010;26:227–36）
